A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese Participants

• Status: Not yet recruiting
• Trial end date: 2023-01-23
• Target enrollment: 0
• Participant gender: All

Summary

The main purpose of this study is to determine the effect of LY3437943 when administered subcutaneously on the levels of midazolam, warfarin and caffeine in the blood stream when administered orally as a drug cocktail in obese participants. This study will last up to approximately 25 weeks for each participant.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Caffeine; Midazolam; Warfarin

Criteria

Inclusion Criteria:

• Body mass index (BMI) within the range 27.0 to 40.0 kilograms per meter squared (kg/m²)

• Male and female participants of childbearing potential who agree to use contraceptive methods

Exclusion Criteria:

• Have a history of diabetes or current diagnosis of diabetes

• History or presence of a of significant bleeding disorder

• Participants with significant comorbidity

• Participants receiving treatment with midazolam, warfarin, inhibitors or inducers of cytochrome P450 (CYP) -1A2, CYP2C9, or CYP3A4 enzymes, or drugs are CYP substrates and have a narrow therapeutic index